were systematically searched for Markov models evaluating DMPs in chronic heart diseases (CHD), diabetes, COPD, asthma, and breast cancer. The quality of the models was evaluated with the help of two different quality appraisals. 
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For patients with chronic conditions disease management programs (DMPs) have been implemented to improve the process and quality of care and to reduce expenditures. The aim here is to present a systematic overview of Markov models evaluating the cost-effectiveness of DMPs; the focus is on the modeling approach for the multiple interventions. Further, the quality of the models and how the differences in structure and data used affect costeffectiveness was evaluated.
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With restrictions to the data selection process, Markov models are adequate to determine the cost-effectiveness of DMPs. However, to allow prioritization of medical services, more flexibility in the models is necessary to enable the evaluation of single additional interventions. According to the results, it is difficult to say in which indication area DMPs are most cost-effective. More recently published models perform slightly better in both quality appraisals. Results are most sensitive to changes in transition probabilities and time horizon. 
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